Kiadis’ proprietary off-the-shelf NK-cell platform is based on NK-cells from a unique universal donor.


We have a pipeline of NK-cell therapies in development as adjunctive therapy for hematopoietic stem cell transplantation and as potential therapeutics for both liquid and solid tumors.

From our cell-based immunotherapy technology platform, we are developing therapeutics as adjunctive treatments for patients undergoing stem cell transplantation and as potentially curative treatments for patients with cancer. Our vision is to leverage the strengths of the human immune system to help patients with life-threatening diseases, by developing novel cell therapies that combine the innate and adaptive arms of the immune system.

Upcoming trials

If you are a medical professional and would like information about becoming an investigator for one of our clinical trials, please contact